Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 7/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394990 | 0.88 | CCR8 (0.78) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5403264 | 0.86 | CCR8 (0.61) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5394526 | 0.86 | CCR8 (0.78) | CCR8KCNH2CYP2D6USP2TSHR | |
| SCHEMBL5399247 | 0.85 | CCR8 (0.60) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5405544 | 0.85 | CCR8 (0.58) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5392143 | 0.84 | CCR8 (0.57) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5402919 | 0.84 | CCR8 (0.57) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5403130 | 0.84 | CCR8 (0.59) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5405353 | 0.84 | CCR8 (0.59) | CCR8KCNH2KDM4EALOX15CYP2D6 | |
| SCHEMBL5389903 | 0.84 | CCR8 (0.71) | CCR8KCNH2CYP2D6USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | claimed |
| JP-2007509141-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | claimed |
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | CCR8, CCR1, CCR10 | CCR8 1/4885KCNH2 2793/4885KDM4E 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.